Loading…
Lobbying Spend
$3.4M
Filings
19
Firms Hired
1
Active Period
2022–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Mikaela Naylon Give Kids a Chance Act
2026 · first_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.
Client expense: $120,000 · Firm income: —
Matched citations: H.R. 1262
Accelerating Kids’ Access to Care Act of 2025
2026 · first_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.
Client expense: $120,000 · Firm income: —
Matched citations: H.R.1509
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.
Client expense: $120,000 · Firm income: —
Matched citations: S.1637
Accelerating Kids’ Access to Care Act
2026 · first_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.
Client expense: $120,000 · Firm income: —
Matched citations: S. 752
Bipartisan Health Care Act
2026 · first_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.
Client expense: $120,000 · Firm income: —
Matched citations: S. 891
Give Kids a Chance Act of 2025
2026 · first_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.
Client expense: $120,000 · Firm income: —
Matched citations: S. 932
Mikaela Naylon Give Kids a Chance Act
2025 · fourth_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.
Client expense: $230,000 · Firm income: —
Matched citations: H.R. 1262
Accelerating Kids’ Access to Care Act of 2025
2025 · fourth_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.
Client expense: $230,000 · Firm income: —
Matched citations: H.R.1509
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.
Client expense: $230,000 · Firm income: —
Matched citations: S.1637
Accelerating Kids’ Access to Care Act
2025 · fourth_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.
Client expense: $230,000 · Firm income: —
Matched citations: S. 752
Bipartisan Health Care Act
2025 · fourth_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.
Client expense: $230,000 · Firm income: —
Matched citations: S. 891
Give Kids a Chance Act of 2025
2025 · fourth_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.
Client expense: $230,000 · Firm income: —
Matched citations: S. 932
Mikaela Naylon Give Kids a Chance Act
2025 · third_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 1262
Accelerating Kids’ Access to Care Act of 2025
2025 · third_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Client expense: $140,000 · Firm income: —
Matched citations: H.R.1509
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Client expense: $140,000 · Firm income: —
Matched citations: S.1637
Accelerating Kids’ Access to Care Act
2025 · third_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Client expense: $140,000 · Firm income: —
Matched citations: S. 752
Bipartisan Health Care Act
2025 · third_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Client expense: $140,000 · Firm income: —
Matched citations: S. 891
Give Kids a Chance Act of 2025
2025 · third_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Client expense: $140,000 · Firm income: —
Matched citations: S. 932
Mikaela Naylon Give Kids a Chance Act
2025 · second_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Client expense: $160,000 · Firm income: —
Matched citations: H.R. 1262
Accelerating Kids’ Access to Care Act of 2025
2025 · second_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Client expense: $160,000 · Firm income: —
Matched citations: H.R.1509
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Client expense: $160,000 · Firm income: —
Matched citations: S.1637
Accelerating Kids’ Access to Care Act
2025 · second_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Client expense: $160,000 · Firm income: —
Matched citations: S. 752
Bipartisan Health Care Act
2025 · second_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Client expense: $160,000 · Firm income: —
Matched citations: S. 891
Give Kids a Chance Act of 2025
2025 · second_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Client expense: $160,000 · Firm income: —
Matched citations: S. 932
Mikaela Naylon Give Kids a Chance Act
2025 · first_quarter · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Reintroduction of Medicaid VBPs for Patients (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). MDRP. CMMI. Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Reintroduction of the Patient Access Act. Bipartisan Health Care Act (S. 891). NIH Funding.
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 1262
Source: Senate LDA